QC
SPRO icon

Quadrature Capital’s Spero Therapeutics SPRO Stock Holding History

Quadrature Capital’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.9K Buy
40,128
+2,329
+6% +$5.53K ﹤0.01% 1232
2025
Q4 		$88.1K Buy
+37,799
New +$87.8K ﹤0.01% 1123
2025
Q3 		– Sell
-31,205
Closed -$90.5K – 1460
2025
Q2 		$90.5K Buy
+31,205
New +$44.9K ﹤0.01% 899

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Quadrature Capital's SPRO Position: Q1 2026 in Review

Quadrature Capital increased its Spero Therapeutics (SPRO) stake by 6.2% in Q1 2026, buying an estimated $5.53K and bringing the position to 40,128 shares worth $93.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1232.

Quadrature Capital first reported a position in SPRO in Q2 2025 and has held it in 3 quarters since. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Quadrature Capital held 40,128 shares of Spero Therapeutics worth $93.9K as of Q1 2026.
  • Quadrature Capital bought 2,329 Spero Therapeutics shares in Q1 2026, an estimated $5.53K.
  • Spero Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1232 holding.
  • Quadrature Capital first reported a position in Spero Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.